Grand Mal Seizure Treatment Global Market Report 2024

The grand mal seizure treatment market size has grown strongly in recent years. It will grow from $1.91 billion in 2023 to $2.02 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth observed in the historical period can be credited to several factors such as advancements in neurological understanding, medical progress, the development of medications targeted at seizures, the establishment of seizure classification systems, and advocacy efforts in legal and social domains. These combined factors significantly contributed to the evolution and improvements in the management and treatment of grand mal seizures during the historical period.

The grand mal seizure treatment market size is expected to see strong growth in the next few years. It will grow to $2.48 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. Anticipated growth in the forecast period can be linked to various factors, including advancements in genetic research and the adoption of precision medicine, the integration of telemedicine for remote patient care, regulatory modifications enhancing accessibility to treatments, advancements in brain imaging techniques, and the application of holistic treatment approaches. Key trends expected in this forecasted period encompass global advocacy initiatives aimed at raising awareness about epilepsy, the establishment of patient-centered care models, increased research focus on seizure genetics, the development of community support networks, and the exploration of non-pharmacological treatment approaches. These trends are likely to influence and contribute to the progression of managing and treating grand mal seizures in the forecasted period.

The anticipated growth of the grand mal seizure treatment market is strongly influenced by the high prevalence of epilepsy. Epilepsy, a neurological disorder characterized by recurring seizures, often manifests as grand mal seizures, which are particularly intense and violent. The rising prevalence of epilepsy worldwide underscores the pressing need for improved treatment options, specifically tailored to address grand mal seizures. As of February 2023, the World Health Organization reported that approximately 50 million people globally were grappling with epilepsy, marking it as one of the most prevalent neurological conditions globally. With an annual diagnosis rate of about 5 million people, the escalating prevalence of epilepsy serves as a primary driver fueling the growth of the grand mal seizure treatment market.

The growth trajectory of the grand mal seizure treatment market is further propelled by the increasing adoption of personalized medicines. Personalized medicine, an innovative healthcare approach, tailors medical treatments to the unique characteristics of individual patients. In the context of grand mal seizure treatment, personalized medicine involves analyzing an individual's genetic and molecular profile to customize interventions, such as selecting medications that are likely to be more effective and better tolerated based on the patient's unique characteristics. This precision-driven approach holds the potential to enhance seizure control while minimizing adverse effects for each patient. In 2022, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), and approximately 34% of these, amounting to 12 NMEs, were classified as personalized medicines by the Personalized Medicine Coalition (PMC). This significant adoption of personalized medicine practices is a key factor driving the growth of the grand mal seizure treatment market.

Major players in the grand mal seizure treatment market are strategically introducing new products, with a focus on anti-epilepsy medications, to gain a competitive advantage. Anti-epilepsy medications, also known as antiepileptic drugs (AEDs) or anticonvulsants, form a crucial class of pharmaceuticals designed to manage and treat epileptic seizures and related disorders. An illustrative example is Zydus Lifesciences Limited, an India-based pharmaceutical company, which, in January 2023, launched Topiramate extended-release capsules in the U.S. market. Zydus achieved the distinction of being the first company to receive final approval and introduce the product in strengths of USP 25 mg, 50 mg, and 100 mg. These capsules are indicated for epilepsy treatment, specifically as initial monotherapy for patients aged six and older with partial-onset or primary generalized tonic-clonic seizures. Additionally, they are approved for migraine prophylaxis in patients aged 12 and older, marking a significant contribution to the evolving landscape of grand mal seizure treatment.

Major companies actively participating in the grand mal seizure treatment market are advancing product development by introducing advanced offerings, particularly small molecule anticonvulsants for refractory focal onset seizures. Small molecule anticonvulsants, characterized by low molecular weight compounds, are instrumental in preventing or controlling seizures in individuals with epilepsy or other neurological disorders. An exemplar in this domain is Xenon Pharmaceuticals Inc., a Canada-based biopharmaceutical company, which launched the Phase 3 program for XEN1101 in November 2022 with the initiation of the X-TOLE2 clinical trial. This trial aims to investigate the use of XEN1101 as an adjunctive treatment for adult patients with focal epilepsy. XEN1101, a differentiated Kv7 potassium channel opener, has garnered positive Phase 2b clinical data, supporting its progression through late-stage clinical development toward commercialization. The introduction of advanced small molecule anticonvulsants represents a strategic move to establish a competitive edge in the dynamic grand mal seizure treatment market.

In March 2022, UCB, a biopharmaceutical company headquartered in Belgium, completed the acquisition of Zogenix for an estimated $1.9 billion. This strategic acquisition is poised to enable UCB to broaden its portfolio within emerging therapy segments and expand its presence in new geographical regions. Zogenix, based in the United States, specializes in the development and production of medications and therapies targeted at treating grand mal seizures. This acquisition signifies UCB's commitment to advancing its offerings in the treatment landscape for grand mal seizures and expanding its global footprint in the pharmaceutical industry.

Major companies operating in the grand mal seizure treatment market report are Pfizer Inc., Johnson & Johnson Inc., Novartis AG, Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceuticals Inc., Mylan N.V., UCB Celltech Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Lupin Pharmaceuticals Inc., Dr. Reddy's Laboratories Ltd., Cipla Inc., Apotex Inc., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Jubilant Life Sciences Limited, Torrent Pharmaceuticals Ltd., Zydus Cadila, Strides Pharma Science Limited, Glenmark Pharmaceuticals Ltd., Wockhardt Ltd., Macleods Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Limited, Indoco Remedies Limited, Spectrum Chemical Mfg. Corp.

North America was the largest region in the grand mal seizure treatment market in 2023. The regions covered in the grand mal seizure treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the grand mal seizure treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Key categories of grand mal seizure treatments include barbiturates, hydantoin, phenyltriazine, iminostilbenes, benzodiazepines, aliphatic carboxylic acids, and other medication classes. Barbiturates function as central nervous system depressants, serving as sedatives, hypnotics, and anticonvulsants. Diagnosis methods may encompass magnetic resonance imaging (MRI), electroencephalogram (EEG), blood tests, computed tomography (CT), and other diagnostic procedures. Treatment options include antiepileptic drugs, surgical interventions, vagus nerve stimulation, ketogenic diet, among others. These treatments cater to various end-users, including academic and research centers, neurological facilities, hospitals, and other healthcare providers.

The grand mal seizure treatment market research report is one of a series of new reports that provides grand mal seizure treatment market statistics, including grand mal seizure treatment industry global market size, regional shares, competitors with a grand mal seizure treatment market share, detailed grand mal seizure treatment market segments, market trends and opportunities, and any further data you may need to thrive in the grand mal seizure treatment industry. This grand mal seizure treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The grand mal seizure treatment market consists of revenues earned by entities by providing deep brain stimulation, complementary therapies, and surgical procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The grand mal seizure treatment market also includes sales of brivaracetam, carbamazepine, clobazam, and felbamate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.